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MANY of the alcohols, phenols and carboxylic acids of mammalian tissue exist
in combination with D-glucuronic acid as /-D-glycopyranosiduronic acids. This
applies tothe steroidhormones and also to various substances, such as stilboestrol,
which are administered therapeutically. The effect of such conjugation is usually
to reduce the biological activity of the substance (Bray, 1953; Teague, 1954).
The hydrolysis of such biosynthetic fi-D-glucopyranosiduronic acids to
D-glycuronic acid and aglycons is catalyzed by the enzyme ,/-glucuronidase which
is under endocrine control (Levvy, 1953).
Kerr and Levvy (1947) and Levvy, Kerr and Campbell (1948) demonstrated
a connection between the level of ,8-glucuronidase in the tissues and processes of
growth and repair.
Goldbarg, Pineda, Banks and Rutenberg (1959) and Whitaker (1960) observed
raised f,-glucuronidase levels in the blood of a proportion of patients with breast
cancer. In 47 cases investigated an abnormally highfI-glucuronidase was observed
in approximately 50 per cent (Whitaker, 1960).
The remission rate following hypophysectomy for metastatic breast cancer
has been estimated by various workers (Luft, Olivecrona, Ikkos, Nilsson and
Ljunggren, 1956; Baron, Gurling and Radley-Smith, 1958) as between 45 and
50 per cent.
The present investigation was undertaken in order to establish whether or
not there was any correlation between the plasma fi-glucuronidase and the
remission rate following hypophysectomy.
MATERIAL
Forty women and one man suffering from metastatic breast carcinoma were
studied. Of these thirty-four were submitted either to open craniotomy or stereo-
taxic implantation of radioactive material into the pituitary with the object of
obtaining complete destruction of the pituitary. This object was achieved in
twenty-eight cases, but in six the operation was abandoned for technical reasons
or the implant did not produce destruction of the pituitary. These six cases are
included as a control group.
The remaining seven cases have been included to illustrate certain effects of
hormone therapy on the plasma ,-glucuronidase.
METHOD
The method of estimation of the plasma f,-glucuronidase has been that of
Tallalay, Fishman and Huggins (1946), modifiedbyBoyland, Wallace andWilliams
(1955).PLASMA /-GLUCURONIDASE AND) BREAST TUMOURS
The normal range of plasma /8-glucuronidase using this method was taken as
0.96-6-20 units, being i two standard deviations about a mean of 3.58 units. This
range was obtained by estimation of the plasma levels of fifty normal women
whose age and menstrual status were listed in a previous communication
(Whitaker, 1960).
Six aspects of the clinical histories of the forty-one patients in this series have
beenstudiedinrelationtoplasmafl,-glucuronidase; namely,theeffectsofandrogens,
oestrogens and cortisone, the relationship of the pre-operative /8-glucuronidase
levels to the response to hypophysectomy, the effect of hypophysectomy itself
on the enzyme, and the relationship of the enzyme to the advance of the disease
process.
(1) The effect ofandrogen administration
Estimations of plasma /l-glucuronidase were made in nineteen cases during or
after the cessation of androgen therapy. In five the androgens were started while
the patient was under observation and in the remainder androgens had been ad-
ministered until the time ofadmission to hospital, when the treatment was stopped.
Group 1, Table I.-Of the five cases who started androgens while under ob-
servation three received methyl testosterone by mouth, one testosterone pro-
pionate by injection, and one case received both in succession.
In four ofthe five cases single pre-therapy observations were made, and in one
eight were obtained.
In three cases testosterone was stopped while the patient was still under
observation, and in column 5, Table I are given the mean f,-glucuronidase values
for each case for the three days following, but not including, the day on which the
drug was stopped. In each case the level off,-glucuronidase continued to rise for
some days after withdrawal of the drug and the maximum level reached before
any subsequent fall is given in column 7, Table I. The other two cases were dis-
charged to terminal homes, still taking testosterone, and in their case the figures
in column 7, Table I represent the last reading before discharge.
Two of the cases who received methyl testosterone showed a sudden sharp
rise in ,-glucuronidase, as illustrated in Fig. 1 (case 91). After withdrawal of the
hormone the f-glucuronidase fell rapidly in each case. Both were subjected to
hypophysectomy and both achieved a major remission. The third case received
a smaller dose of methyl testosterone (5 mg. t.d.s.) and at the time of discharge
five days later the ,-glucuronidase had risen by 1.31 units.
Case 39, unlike the other four cases, had a greatly elevated pre-therapy reading
(13-9 units). She was treated at first with injections of 100 mg. testosterone pro-
pionate intramuscularly on alternate days for eight doses. Following an initial
peak of 18.9 units the i-glucuronidase returned gradually to its original level by
the time the eighth dose had been given. For the next seven days she received
methyl testosterone by mouth, 20 mg t.d.s., with a further fall of/8-glucuronidasc
to 10-2 units At this time she had a sudden increase in pain from bone deposits
and the treatment was altered to 200 mg. testosterone propionate intramuscularly
on each of the next three days. Coincident with this there was a rise of f8-glucu-
ronidase to 19.4 units, though whether due to the increase androgen or to advance
of the disease is not clear. This patient did not respond to hypophysectomy.
Case 105 received intramuscular testosterone propionate 100 mg. on alternate
days. After 11 days the ,-glucuronidase had fallen by 2-1 units.
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TABLE II.-Androgen Therapy Until Admission
Initial
reading Interval Last reading
Case fl-glucuro- since before other Interval
Number nidase androgens treatment (days)
<1) Oral Methyl Testosterone:
Type, dose and
duration of
androgen therapy
7 . 11·20 . 1 day . 5-45 . 9 . Meth. test.
15 mg. t.d.s.
6 weeks
13 . 13-40 . 5days . 4-20 . 17 . Meth. test.
15 mg. t.d.s.
14* . 9.05 . 1 day . 260 . 10 . Meth. test.
5 mg. t.d.s.
1 month
16 . 8.70 . 16days . 4-80 . 34 . Meth. test.
15 mg. t.d.s.
1 year
81 . 23.5 . I day . 12-60 . 7 . Meth. test.
15 mg. t.d.s.
1 month
100 . 980 . 1 day . 10.50 . 20 . Meth. test.
15 mg. t.d.s.
3 months
(ii) Testosterone propionate by intramuscular injection:
Response to
hypophysectomy
Group III
. Pituitary function
not abolished
Group I
Group I
Group IV
Group IV
9 . 3 92 . Androgens.
continued
until op.
14* . 2-60 . 2 days .
88 . 4.40 1 day
103 . 6.20 . 7 days
3-55 . 48 . Test. prop.
200 mg./day
56 days
- . Test. prop.
100 mg. daily
5 days
5-32 . 3 . Test. prop.
100 mg. daily
7 months
4-56 . 22 . Test. prop.
6 months
· Pituitary function
not abolished
Group I
Group I
Group IV
(iii) Non.virilizing Androgens:
23 . 2-21 . 5 days .
28 . 5.05 1 day
106 . 10-70 . 1 day
107 . 6-85 1 day
3.10 . 7 . Androstalone
25 mg. t.d.s.
for 4 yr then
50 mg. t.d.s.
for 3 months
. Durabolin
3 months
10-*12 . 14 . Androstalone
25 mg. t.d.s.
2 months
6- 70 . 6 . Durabolin
25 mg. weekly
6 months
Group I
Pituitary function
not abolished
Pituitary function
not abolished
* After withdrawal of oral methyl testosterone from Case 14 her f-glucuronidase fell over the
next ten days to 2.6 units. During this ten days she was given intramuscular testosterone propioniate.
Group 2, Table II -In this group of fourteen cases six had had oral methyl
testosterone, four intramuscular testosterone propionate and four non-virilizing
androgens in the form of" Durabolin" (norandrostenolone phenyl propionate) in
two cases and "androstalone" (methyl androstanolone) in the other two. In
each of the fourteen the androgen was discontinued just before admission.
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In Column 4, Table II, are given the last available figures for 8-glucuronidase
following withdrawal of androgens and before the start of any other hormonal
treatment.
(i) In the six cases who had had oral methyl testosterone the maximal interval
between cessation of androgens and the first f-glucuronidase assay was sixteen
days. This case showed the lowest initial level of the six (8.7 units).
O0
.~ '. -.
.._...
tE .,.w:
. '.~ --- " ' · · .-'.
FIG. 1.-The effect of oral methyl testosterone on the plasma fl-glucuronidase (Case 91).
The dotted line represents the upper limit of normality.
On withdrawal of testosterone a fall in ,-glucuronidase of over five units
occurred in four cases, of over two units in one, and a slight rise (0.7 units) in one.
(ii) Four cases receiving intramuscular testosterone propionate until admis-
sion all had normal f,-glucuronidase readings. After stopping the drug a slight fall
occurred in one and a rise in another. In the third case (No. 9).testosterone was
continued until the day of operation.
Case 14 is of interest in that she was admitted, immediately after a course of
methyl testosterone by mouth, with an initial reading of 9-05 units offI-glucuro-
nidase. After stopping the testosterone the glucuronidase level began to fall and
continued to do so, eventually reaching 2.60 units, even though the patient com-
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menced a course of intramuscular testosterone propionate 200 mg. daily four
days after admission (Fig. 2).
(iii) Two of the four cases admitted after a course of non-virilizing androgens
had initial readings within normal limits, one was slightly raised, and the fourth
was very high. Of the three for whom readings are available after withdrawal of
the hormone none showed any appreciable change.
In all, therefore, ten cases had oral methyl testosterone, and all ten had ab-
normally high f,-glucuronidase levels while taking the drug or immediately after
it had been discontinued. Eight of the ten showed a fall in /8-glucuronidase sub-
sequent to withdrawal of testosterone.
Of the 9 cases given intramuscular testosterone propionate or non-virilizing
androgens only one case showed marked elevation ofthe ,-glucuronidase, and this
did not fall when the androstalone was stopped.
j !, .....1,! t,.,: :;!~ ~,:..:~ i.
'4.
i! /:: ::? 0 : /!\ !?< ::
* ::~ ?i ': ~i ,$;
.0~~~~~~~~~~----- -- --:
r, * 0eP,, ' Ta
Fic. 2.-Case 14. High fl-glucuronidase on admission after a course of methyl testosterone by
mouth as an out-patient. On withdrawal ofthe methyl testosterone the fl-glucuronidase fell,
and this fall was not checked by the administration ofintramuscular testosteronepropionate.
The dotted line represents the upper limit of normality.
(2) The effect of ethinyl oestradiol and stilboestrol
Nine cases received ethinyl oestradiol or stilboestrol. Six of these were under
observation before the start of oestrogen therapy. They were each given ethinyl
oestradiol in large doses by mouth for periods varying from four to twelve days,
after which the drug was discontinued.
The pre-oestrogen mean ,-glucuronidase for each case is given in Column 2,
Table III. The mean fl-glucuronidase values for the three days following, but not
including the day on which the oestrogens were stopped, are given in Column 5,
Table III, for the four cases in whom such measurements were possible.
The maximum levels reached after the end of the course, and before any
subsequent fall in fl-glucuronidase, are given in Column 7, Table III.
In all six cases a rise of fl-glucuronidase was observed. This was marked in
four and moderate in two. Three other cases had received stilboestrol until the
time of admission (Table IV).B. L. WHITAKER
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All three cases had an initially high fi-glucuronidase. After withdrawal of the
drug two showed a marked fall in the enzyme level. The third showed a slight fall
but died as a result of a cerebral vascular accident after only thirteen days.
3. The effect of cortisone
In six cases pituitary ablation was attempted, but for various reasons not
achieved. In one case severe bleeding from the fossa prevented removal of the
pituitary, and in another a pre-fixed chiasm was present. In both cases 198Au
seeds were injected into the gland after it had been broken up as far as possible
with a sharp probe. The third case was abandoned because ofuncontrollable intra-
cranial haemorrhage, and the fossa was not opened. The remaining three cases
had 198Au seeds implanted into the pituitary fossa by a stereotaxic technique
(Bennett, 1950).
In the case with a pre-fixed chiasm (No. 30) thyroid function became slightly
depressed post-operatively. However she continued to menstruate and the corti-
sone withdrawal test (Baron and Gurling, 1960) suggested that pituitary destruc-
tion was incomplete. In the remaining five cases no evidence of diminished
pituitary function was obtained, and in all six cases the progress of the disease
was unaffected.
The three cases subjected to open operation were given cortisone 100 mg.
intramuscularly on the day before operation, 175-200 mg. intramuscularly and
intravenously on the day of operation, and thereafter steadily decreasing doses
until a maintenance dose of 25 mg. b.d. was reached on the tenth post-operative
day.
Two ofthe cases submitted to stereotaxis did not start cortisone until nineteen
and twenty-three days postoperatively. The third received prednisone 40 mg.
daily for seven days before and for fourteen days after operation.
Two cases (No. 106 and 107) had received non-virilizing androgens until their
admission. Case 13 had had methyl testosterone by mouth until admission, and
the pre-cortisone level for this case is therefore taken as the single estimation
immediately before operation and fourteen days after admission. Case 9 had
received intramuscular testosterone propionate and also thiotepa until just before
the gold implantation, and therefore the last single estimation before operation
is taken as the pre-cortisone level of /8-glucuronidase. Cases 30 and 25 had had
no previous treatment.
In each case subsequent estimations of /8-glucuronidase have been grouped
according to the number of weeks elapsing since the start of cortisone therapy.
The mean figures for each week are given in Table V.
Each of the three cases submitted to open operation showed a slight rise in
f/-glucuronidase in the first post-operative week, followed in later weeks by a fall
towards the pre-operative level. The fall in enzyme level noted in the second and
third post-operative weeks for Case 30 may be due to the fact that she received
treatment with saccharo-1: 4-lactone, a glucuronidase inhibitor.
In the two cases treated by stereotaxic implantation who did not start corti-
sone until some weeks after operation, apost-operative rise of/f-glucuronidase was
also observed (not shown in Table V). Estimations made after the start of corti-
sone therapy, however, do not differ greatly from the pre-operative figures.
Case 25 showed a moderate fall in f,8-glucuronidase, coincident with the start
of prednisone. When this treatment was stopped the enzyme returned to its
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former level. None of the five cases treated with cortisone shows any comparable
alteration in enzyme level.
(4) The relationship ofpre-operativef/-glucuronidase and response to hypophysectomy
Pituitary ablation was performed in twenty-eight patients, twenty-one by
open operation and seven by stereotaxic implantation of 90Y rods into the fossa.
The results of these operations are classified into four groups:
I. Major regression.-Objective and subjective improvement maintained for
more than two months.
II. Minor regression.-Subjective improvement maintained for more than two
months or apparent cessation in spread of a formerly advancing lesion.
III. Doubtful group.-Equivocal subjective or objective improvement, or
improvement lasting less than two months.
IV. Failed group.-Those cases in whom no objective or subjective improve-
ment was obtained, and those dying within one month of operation.
Groups I and II combined are approximately equivalent to the "remission"
group of Luft, Olivecrona and Ikkos (1958).
In view of the findings in respect of the effect of androgen and oestrogen
administration on ,-glucuronidase a direct comparison between the uncorrected
pre-operative mean /?-glucuronidase levels would obviously be misleading. An
attempt has been made to correct for the effect of androgens by calculating the
mean ,-glucuronidase, either from estimations made before the administration
of androgens, where this is possible, or from estimations made over a month after
the cessation of androgen therapy. In a number of cases the hypophysectomy
was performed within a month ofthe cessation of androgens, and these have been
excluded from the calculation.
Two cases (No. 70 and 98) had received oestrogens until just before admission,
and a further two (No. 55 and 104) had already undergone ablative endocrine
surgery in the form of oophorectomy and adrenalectomy respectively, to which
they had responded. These cases are also excluded.
When these corrections have been made nine cases are left in the combined
I and II groups and ten cases in the combined III and IV groups (Table VI).
The mean ,-glucuronidase level for the combined groups I and II is 5.74 units,
while that for the combined groups III and IV is 9-22 units. This difference is
statistically significant (t 2.70, P - <0.02). If still more rigorous selection is
carried out by excluding Cases 99, 102 and 96 who received prednisone until the
time of their admission, Case 94 who survived only four days after implant of
90Y and Case 91 whose pre-operative 131I uptake was in the thyrotoxic range the
numbers in groups I and II are reduced to eight and in groups III and IV to six.
The mean values are 5-58 and 10-61 respectively, and the difference is still signi-
ficant (t 3.63, P = <0.01).
These figures are represented, graphically, together with subsequent changes
in ,-glucuronidase levels in Fig. 3 and 4.
(5) The effect of hypophysectomy on plasma f/3-glucuronidase
In ordertopresent the available figures in a comparable formthepost-operative
estimations for each hypophysectomy patient are given as mean values for each
post-operative week. Table VII is calculated from a total of 292 pre- and post-
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operative figures. Those marked with an asterisk are those who were excluded
from the calculation in Section 4 above, because of recent androgen or oestrogen
administration. The figures in brackets represent the number ofestimations from
which each mean value has been calculated. Fig. 3 and 4 are a graphic representa-
tion ofTable VII after exclusion ofthe cases marked with an asterisk.
It will be observed firstly that in all group I and II cases save one (No. 14)
there is either no great alteration in level or else a downward trend of the 8-
glucuronidase (Fig. 3). Secondly only two cases show elevation above 7.5 units
at any point.
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FIG. 3.-Cases responding favourably to hypophysectomy. Serial fl-glucuronidase estimations
before andafter operation. The dotted line represents the upperlimit ofnormality, the heavy
continuous line the normal mean fl-glucuronidase plus three standard deviations.
In groups III and IV however the variations from weektoweekaremuchmore
pronounced, there is no general tendency up or down and all save two are greater
than 7.5 units (mean normal value plus three standard deviations), at some point
(Fig. 4).
(6) The effect of advance in the disease process on the plasma j8-glucuronidase
Twelve cases were followed for periods of over three months. The first avail-
able figure for each case is shown in Column 3, Table VIII. Wherever possible
these figures refer to a period at least one month after cessation of androgen or
oestrogen therapy, but in four ofthe cases this does not apply (No. 23, 7, 9 and 96).
Each of these had received androgen therapy within one month of the initial
reading quoted.
50
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At the time of their last available estimations five cases were in remission or
static, and the mean net rise for these five cases is 0.75 units over eight months.
All but one of the five final readings were within the normal range.
20
va
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·~~~~~~~~~ "~ ~~
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EL 4
3
2,
Ist. 2nd. 3rd. 4th.
preoperative post-operative post-operative post-operative post-operative
week- week week week
FIc. 4.-Cases responding unfavourably to hypophysectomy. Serial fl-glucuronidase estima-
tions before and after operation. The dotted line represents the upper limit ofnormality, the
heavy continuous line the normal mean fl-glucuronidase plus three standard deviations.
The remaining seven cases showed signs of advancing disease at the time of
thefinal readingand the mean net rise forthisgroup is 3.98 unitsover 5.8 months.
The final readings of all but one of the seven were outside the normal range.
DISCUSSION
Cohen (1951) gave testosterone to six patients, but noted a rise in serum fi-
glucuronidase in only one. Fishman (1951) found that methylandrostenediol
produced a rise in the serum enzyme level in a proportion of cases.
In this series administration of testosterone by mouth was fairly consistently
associated with a rise in plasma f-glucuronidase, whereas testosterone propionate
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TABLE VII.-The Effect ofHypophysectomy on Plasma f-glucuronidase
Case Pre-op.
Number fl-glucuronidase
14 . 9,56 (4)
16 . 6-60 (2)
23* . 3- 67 (4)
48 . 4.84 (3)
70* . 23-40 (3)
86 . 4.57 (3)
87 . 4 36 (4)
88* . 4.54 (4)
89* . 4-33(1)
91 . 7.00 (1)
43 . 3-50 (2)
92 . 6.94 (4)
2 . 15-65 (2)
7* . 908 (5)
39* . 13-90 (1)
93
55*
81*
94
95
96
97
98*
99
100
102
103*
109*
9 00 (2)
4- 72 (9)
18.80 (4)
6-23 (4)
8.91 (7)
10*24 (6)
7.40 (6)
8- 76 (2)
8.02 (7)
8- 80 (1)
5-02 (4)
6-49 (8)
5-67 (15)
1st post-op.
week 2nd week
10.79(3) 7.96(1)
7.00 (1) -
4.-72 (2) 5.32 (2)
7.02 (3) -
18-05 (2) . 12.09 (3)
5.28 (4) . 4.-82 (2)
7.15 (1) . 3-85 (2) 5.53(1) . 3.78(1)
6-55 (3) . 9.04 (1) 5.56 (2) . 4.40 (1)
- 5-40 (1)
4.-50 (1) 4.40 (2)
- . 13.50 (1)
6.93 (2) . 6.-63 (4)
20-70 (4) . 15.68 (3)
(androgens
intervening)
16.12 (1) . 7-31 (2)
- . 10-90 (1)
8.02 (4) . 4.05 (1)
9-25 (1) -
10.39 (2) . -
9-80 (1) -
6.-66 (4) 6.34 (1)
6.19 (2) . 2-53 (2)
13.23(1) . 9.95(2)
8.35 (3) . 10- 30 (2)
4.28 (3) . 4.79 (2)
5- 52 (2) . 3- 87 (2)
11.20 (2) .7-12 (2)
3rd week
7-00(2)
7-25 (2)
4.68 (3)
. 14.70 (1)
5.67 (2)
1.79 (2)
1.60 (2)
4.60 (3)
4.-52 (2)
4.83 (2)
3.75 (1)
5.54 (1)
. 14-70 (2)
4-51 (3)
6.11 (3)
2-11 (1)
12.72 (3)
9.80 (1)
5.46 (3)
4th week
4 80 (2)
6 79 (3)
3-11 (2)
9-50 (2)
8 30 (3)
1.35 (1)
3-67 (3)
3.02 (1)
4.11 (2)
3.65 (3)
13.90 (1)
4 32 (4)
19.45 (2)
7.24 (1)
3.13 (2)
7.93 (4)
14-06 (3)
11*61 (1)
6.35 (1)
4.86 (1)
Response to
hypophysectomy
Group I
Group II
Group III
Group IV
Group IV
,,
,,
* Cases excluded from the calculation in Section 4 of Methods.
The figures in brackets represent the number of estimations from which each mean value has
been calculated.
TABLE VIII.-Relation ofPlasma fl-glucuronidase to Deterioration in Clinical State
Period of
Case follow-up
Number (months)
7
9
13
14
4
5
16 . 10
36 . 9
23
30
6
6
First
available
reading
3.94
(Test. prop.)
3-92
(Test. prop.)
4-20
6-60
3-07
3-67
(Androstalone)
1 -9
12 . 3 . 2-29
(post-
hypophysectomy)
43 . 8 . 2- 96
48 . 7 . 4-84
96 6 . 3 25
(Methyl test.)
100 . 3 . 8- 80
Last
available
reading
7-02 .
Rise Response
or to
fall hypophysectomy
+3-08 . Group III
7-10 . +3'18 . Pituitary
not destroyed
8- 65 .+44-45 . Pituitary
not destroyed
5- 20 . -1-4 . Group I
3.45 . +0 38 . Pituitary
not destroyed
5.4 . +1- 73 Group I
4-10 . +2-20
8- 10 . +5-81
6-85
3-56
9-80
11'90
Pituitary
not destroyed
Group IV
+3- 89 . Group II
-1.28 . Group I
+6- 55 . Group IV
State at time
oflast avail-
able reading
. Deteriorating
. Deteriorating
. Deteriorating
. In remission
Static
. Deteriorating
Static
. Deteriorating
Static
. In remission
. Deteriorating
. +3-10 . Group IV . Deteriorating
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administered intramuscularly did not produce a similar rise. Possibly this dif-
ference is due to a difference in conjugation of the testosterone according to its
route of absorption.
No constant effect was demonstrated as a result of administration of non-
virilizing androgens.
Other workers have frequently observed a rise in blood glucuronidase following
administration ofboth natural and synthetic oestrogenic substances (Cohen, 1951;
Goldbarg, Pineda, Banks and Rutenburg, 1959; Fishman, 1951; Cohen and
Huseby, 1951) and these findings are confirmed by the present investigation. The
fact that stilboestrol produces a similar effect on plasma glucuronidase to that of
naturally occurring oestrogens, in spite ofthe lack ofany chemical similarity, may
be due to the metabolism of stilboestrol via its monoglucuronide.
Cohen (1951) reported that cortisone produced a rise in serum f-glucuronidase
levels in man, but in this series no constant effect has been observed, either in the
control group of six "sham-operated" cases or in those whose pituitaries were
destroyed, though one case (No. 25) showed a fairly marked fall on prednisone
therapy. A high proportion of cases showed a slight rise in /8-glucuronidase in the
firstpost-operative week, but this is probably anon-specific effect oftraumasimilar
to the effect on urinary ,8-glucuronidase described by Boyland and Williams (1956)
and Lewis and Plaice (1960).
A low plasma fl-glucuronidase seems to be associated with a significantly
greater chance of remission following hypophysectomy than is a high level. This
is not an absolute criterion; for instance Case 102 showed no response what-
soever to hypophysectomy yet had a pre-operative mean fl-glucuronidase of 4.57.
It may perhaps be significant that this patient had been taking prednisone until
admission fourteen days before operation, and had shown a good response to
hormone therapy in the past.
The percentage remission rate in the present series, after excluding those
cases affected by recent androgen or oestrogen therapy is shown in Table IX.
TABLE IX
fl-glucuronidase Percentage remissions
0.96-6.20 . 83-5
(norma] range)
6-20-7*50 . 60
(normal mean + S S.D.
to mean + 3 S.D.)
7-50+ . 12-5
These percentages are of course calculated from a relatively small sample and
will probably require modification as more figures accumulate. Assuming how-
ever that they are fairly near the true figures the estimation of the plasma f-
glucuronidase might well prove to be of value in deciding the form of therapy to
adopt in a poor risk case. A figure of over 7-5 units, in the absence of previous
hormone therapy, would be an indication for chemotherapy, rather than surgery.
The relationship oftheplasma ,-glucuronidase to the effect ofhypophysectomy
is probably indirect, certainly a fall in glucuronidase is not a necessary pre-
requisite of remission, nor does a fall in f-glucuronidase necessarily indicate that
a remission is taking place.
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In a number of patients the plasma fl-glucuronidase was artificially lowered
by oral administration of saccharo-l: 4-lactone, a glucuronidase inhibitor, with-
out any obvious change in the course ofthe disease. Probably the fl-glucuronidase
is merely an index of the relative proportions of the free and combined fractions
of various steroids.
Finally, with regard to the relationship of the f8-glucuronidase to advance in
the disease process, Table VIII does suggest a direct relationship when the disease
is followed over a sufficiently long period, a finding which is at variance with those
of Cohen and Huseby (1951).
SUMMARY
Plasma /8-glucuronidase levels of forty women and one man suffering from
breast carcinoma have been studied.
(1) A rise in enzyme level was associated with administration of oral methyl
testosterone, ethinyl oestradiol or stilboestrol.
(2) Intramuscular testosterone propionate, non-virilizing androgens and cor-
tisone did not produce any constant effects on the enzyme.
(3) A comparison of the pre-operative fi-glucuronidase levels of nineteen cases
submitted tohypophysectomy showed a statistically significant difference between
those who responded to the operation and those who did not. A low pre-operative
level appeared to be associated with a high proportion of remissions.
(4) Follow-up cases over a prolonged period showed increasing enzyme titres
with deterioration in the clinical condition.
(5) The significance of these results is discussed and it is suggested that the
fl-glucuronidase may prove to be a useful index of hormone sensitivity of breast
carcinomas, providing the patient has not been receiving hormone therapy imme-
diately before the estimation is made.
I should like to express mythanks to Mr. E. J. Radley-Smith for his encourage-
ment of this project and for permission to study his cases. Also Dr. D. N. Baron
and Dr. D. C. Williams for their guidance and expert advice on the technical and
biochemical aspects of the investigation, Dr. Evelyn Boesen, Dr. Avery Denfield,
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